Dianthus Therapeutics (DNTH) EBT Margin (2022 - 2025)
Dianthus Therapeutics' (DNTH) quarterly EBT Margin came in at 41708.33% in Q3 2025, down 3827919.0% year-on-year from N/an in Q3 2024, and down 59.18% quarter-over-quarter from 26202.07% in Q2 2025.
Dianthus Therapeutics (DNTH) EBT Margin (2022 - 2025) Analysis & Trends
Dianthus Therapeutics' EBT Margin history runs 4 years deep, the most recent figure standing at 41708.33% for Q3 2025.
- On a quarterly basis, EBT Margin fell 3827919.0% year-over-year to 41708.33% in Q3 2025; TTM through Sep 2025 was 9216.73%, a 600085.0% decrease from a year earlier, with the FY2024 full-year figure at 4267.91%, up 179784.0% from the prior year.
- EBT Margin fell to 41708.33% in Q3 2025 per DNTH's latest filing, from 26202.07% in the prior quarter.
- Across five years, EBT Margin topped out at 855.57% in Q4 2022 and bottomed at 41708.33% in Q3 2025.
- The 4-year median for EBT Margin is 2434.52% (2023), against an average of 7193.87%.
- Across the five-year window, EBT Margin surged 146118 bps in 2024 and sank 3827919 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 855.57% in 2022, then plunged by 285 bps to 3297.16% in 2023, then surged by 44 bps to 1835.97% in 2024, then sank by 2172 bps to 41708.33% in 2025.
- Per Business Quant, the three latest DNTH EBT Margin figures stand at 41708.33% (Q3 2025), 26202.07% (Q2 2025), and 3918.42% (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Dianthus Therapeutics | 3.37 Bn | 2.97 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -41,708.33% |
| Jun 30, 2025 | -26,202.07% |
| Mar 31, 2025 | -3,918.42% |
| Dec 31, 2024 | -1,835.97% |
| Sep 30, 2024 | -3,429.14% |
| Jun 30, 2024 | -3,488.84% |
| Mar 31, 2024 | -2,061.56% |
| Dec 31, 2023 | -3,297.16% |
| Sep 30, 2023 | -2,434.52% |
| Jun 30, 2023 | -1,211.87% |
| Mar 31, 2023 | -1,490.34% |
| Dec 31, 2022 | -855.57% |
| Sep 30, 2022 | -1,586.53% |